Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Biomark Diagnostics Inc. (C:BUX)

Business Focus: Diagnostic & Testing Substances Manufacturers

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for BUX within the last 6 months
See all filings within the past 6 months

Company News

Jun 01, 2021 08:30 ET
BioMark Receives $825K Grant to Develop Its Liquid Biopsy Assay for Lung Cancer Screening
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. ("BDS") received funding to develop an early-stage lung cancer screening assay using BioMark's proprietary liquid biopsy platform. The total sponsored research grant is about $825,000 and a major portion of the funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+) and Spark grant from the Canadian Cancer Society (CCS, grant # 707073), the Canadian Institutes of Health Research - Institute of Cancer Research (CIHR-ICR, grant # 0590008438), and Brain Canada Foundation.
Read full article
May 31, 2021 08:30 ET
BioMark Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2021) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark") announces that it has changed its auditors from Manning Elliott LLP ("Former Auditor") to PricewaterhouseCoopers LLP ("Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors of the Company appointed the Successor Auditor effective as of the same date, until the next Annual General Meeting of the Company.
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 20214,381-13,918
May 31, 202118,299-68,077
May 15, 202186,37651,880
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Biomark Diagnostics Inc. is an analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting investigational new drug (IND) and new drug application (NDA)-enabling studies. The Company is engaged in the cancer diagnostics using metabolites. The Company's metabolomics-based diagnostic assay allows cancer detection. The assay consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement through liquid chromatography mass spectrometry (LC MS) in body fluids. This acetylation is performed by the enzyme, spermine/spermidine N-acetyl transferase (SSAT). SSAT is observed in various cancers, including lung, breast, prostate, melanoma and gastrointestinal (GI) cancers. The analysis of SSAT messenger ribonucleic acid (mRNA) levels in tissue samples allows determination of cancer type.

See business summary



Search (past week) for $BUX.CA

  • No tweets found